Evicenter
MarkdownMedical informationP&T meetings
Emcitate (tiratricol)

MCT8 deficiency

Last updated
81 sources

Section 6 of 6

References

81 sources

  1. Anderson et al. (2026) (opens in a new tab)
  2. Bárez-López et al. (2016) (opens in a new tab)
  3. Bauer et al. (2024) (opens in a new tab)
  4. Becker et al. (2024) (opens in a new tab)
  5. Boelaert et al. (2026) (opens in a new tab)
  6. Çelik et al. (2025) (opens in a new tab)
  7. Chan et al. (2022) (opens in a new tab)
  8. Chen et al. (2023) (opens in a new tab)
  9. ClinicalTrials.gov NCT02396459 (opens in a new tab)
  10. ClinicalTrials.gov NCT05579327 (opens in a new tab)
  11. Costa et al. (2026) (opens in a new tab)
  12. Dietrich et al. (2026) (opens in a new tab)
  13. Dubinski et al. (2025) (opens in a new tab)
  14. Egetis Therapeutics approval announcement (2026) (opens in a new tab)
  15. Egetis Therapeutics Breakthrough Therapy designation announcement (2025) (opens in a new tab)
  16. Egetis Therapeutics Clinical Trials and Managed Access (opens in a new tab)
  17. Egetis Therapeutics EMCITATE prescribing information (2026) (opens in a new tab)
  18. Egetis Therapeutics EMCITATE prescription and enrollment form (2026) (opens in a new tab)
  19. Egetis Therapeutics ETA and ESPE congress presentations announcement (2026) (opens in a new tab)
  20. Egetis Therapeutics Fast Track designation announcement (2021) (opens in a new tab)
  21. Egetis Therapeutics first quarter 2026 interim report (2026) (opens in a new tab)
  22. Egetis Therapeutics long-term efficacy and safety data announcement (2021) (opens in a new tab)
  23. Egetis Therapeutics NDA acceptance and priority review announcement (2026) (opens in a new tab)
  24. Egetis Therapeutics ReTRIACt results announcement (2025) (opens in a new tab)
  25. Egetis Therapeutics rolling NDA review announcement (2025) (opens in a new tab)
  26. Egetis Therapeutics rolling NDA submission completion announcement (2026) (opens in a new tab)
  27. Egetis Therapeutics second quarter 2026 interim report (2026) (opens in a new tab)
  28. Egetis Therapeutics survival data announcement (2024) (opens in a new tab)
  29. Egetis Therapeutics Triac Trial II topline results announcement (2024) (opens in a new tab)
  30. Egetis Therapeutics U.S. launch announcement (2026) (opens in a new tab)
  31. European Medicines Agency (2024) (opens in a new tab)
  32. European Medicines Agency Emcitate assessment report (2024) (opens in a new tab)
  33. European Medicines Agency Emcitate EPAR (opens in a new tab)
  34. European Medicines Agency Summary of Product Characteristics (opens in a new tab)
  35. FDA Emcitate approval announcement (2026) (opens in a new tab)
  36. FDA Novel Drug Approvals (2026) (opens in a new tab)
  37. FDA Orphan Drug Designations and Approvals (2019) (opens in a new tab)
  38. Freund et al. (2024a) (opens in a new tab)
  39. Freund et al. (2024b) (opens in a new tab)
  40. Freund et al. (2026) (opens in a new tab)
  41. G-BA justification to the resolution on tiratricol (2025) (opens in a new tab)
  42. G-BA resolution on tiratricol (2025) (opens in a new tab)
  43. Gazek et al. (2023) (opens in a new tab)
  44. Groeneweg et al. (2019) (opens in a new tab)
  45. Groeneweg et al. (2020) (opens in a new tab)
  46. Groeneweg et al. (2025) (opens in a new tab)
  47. Groeneweg et al. (2026) (opens in a new tab)
  48. Haute Autorité de Santé Emcitate opinion page (2025) (opens in a new tab)
  49. Haute Autorité de Santé Transparency Committee summary opinion (2025) (opens in a new tab)
  50. Investing.com Jefferies Global Healthcare Conference transcript (2026) (opens in a new tab)
  51. IQWiG (2025) (opens in a new tab)
  52. ISRCTN ISRCTN98332431 (opens in a new tab)
  53. Iwayama et al. (2021) (opens in a new tab)
  54. Kersseboom et al. (2014) (opens in a new tab)
  55. Kubota et al. (2022) (opens in a new tab)
  56. Lamb (2025) (opens in a new tab)
  57. Manders et al. (2026) (opens in a new tab)
  58. McWalter et al. (2025) (opens in a new tab)
  59. National Organization for Rare Disorders (2025) (opens in a new tab)
  60. NCATS Global Substance Registration System (opens in a new tab)
  61. Ofori et al. (2024a) (opens in a new tab)
  62. Ofori et al. (2024b) (opens in a new tab)
  63. Ofori et al. (2025) (opens in a new tab)
  64. Papademetriou et al. (2026) (opens in a new tab)
  65. Persani et al. (2024) (opens in a new tab)
  66. Pharmaphorum (2026) (opens in a new tab)
  67. Pribilincová et al. (2025a) (opens in a new tab)
  68. Pribilincová et al. (2025b) (opens in a new tab)
  69. Salas-Lucia et al. (2024) (opens in a new tab)
  70. Sarret et al. (2020) (opens in a new tab)
  71. Sonesson et al. (2024) (opens in a new tab)
  72. Ünsal and Hayran (2024) (opens in a new tab)
  73. van der Most et al. (2024) (opens in a new tab)
  74. van Geest et al. (2022) (opens in a new tab)
  75. van Geest et al. (2023) (opens in a new tab)
  76. van Geest et al. (2026) (opens in a new tab)
  77. Verge et al. (2012) (opens in a new tab)
  78. Visser et al. (2016) (opens in a new tab)
  79. Weiss et al. (2024) (opens in a new tab)
  80. Wilpert et al. (2023) (opens in a new tab)
  81. Zung et al. (2024) (opens in a new tab)